Antitope Ltd., a Cambridge UK-based biotechnology company, and Therapure Biopharma Inc., Canada (Therapure), an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins, has signed a research agreement for the generation of therapeutic monoclonal antibodies.

Under the terms of the agreement, Antitope will apply its proprietary Composite Human Antibody technology for the generation of humanized antibodies for a range of clinical indications.

“We are delighted to be working with such an innovative company as Therapure,” said Dr Matthew Baker, chief scientific officer and co-founder of Antitope, adding, “This partnership utilizes Antitope's expertise in engineering non-immunogenic humanized antibodies to complement Therapure's innovations in developing novel therapeutics based on monoclonal antibodies.”

“Therapure is pleased to work with Antitope to develop humanized monoclonal antibodies to support our drug development programmes. This is an important next step in the development of our antibodies,” said Dr David Bell, chief scientific officer of Therapure.